SpliceBio

SpliceBio takes over Times Square! 🗽 Proud to see our $135M Series B milestone spotlighted on the iconic @Nasdaq Tower. Huge thanks to our team & investors powering the next wave of genetic medicines! 💡

#Stargardt disease has no approved treatments. This #HealthyVisionMonth, we’re raising awareness of inherited retinal diseases. At SpliceBio, we’re working to advance genetic medicines using protein splicing to address diseases caused by mutations in large genes.

We’re heading to #ASGCT2026 next week! Looking forward to connecting with the community, sharing insights, and contributing to the conversation around #genetherapy at the @ASGCTherapy Annual Meeting. See you there!

Great science starts with great people. Today, we celebrate the SpliceBio team whose passion and collaboration power our work in genetic medicines. Thank you for all you do. Happy #InternationalWorkersDay!

Happy #SantJordi and #WorldBookDay 🌹📖 Today, we’re celebrating a Catalan tradition of books, roses and storytelling with our team in Barcelona. Here’s to a day of love and culture, with roses for all!

Feliç #SantJordi i #WorldBookDay 🌹📖Avui celebrem una tradició catalana de llibres, roses i històries amb el nostre equip a Barcelona. Un dia per celebrar l’amor i la cultura, amb roses per a tothom!

Details: fightingblindness.org/events/innovat…

Our CMO Aniz Girach will present at the Annual Retinal Therapeutics Innovation Summit in Denver, co-hosted by @FightBlindness and @CaseyEye. He’ll share the progress of our clinical program SB-007, a third-generation intein-based dual AAV in development for Stargardt disease.

Watch here: checkrare.com/investigationa…

Our co-founder and CEO sat down with @CheckRare to discuss SB-007, our investigational dual-AAV gene therapy for #Stargardt disease, and how it is designed to enable delivery of the full-length ABCA4 protein.

Our work in genetic medicines is guided by shared values and scientific excellence. We’re grateful to the women at SpliceBio and to those everywhere whose work helps translate discovery into transformative therapies for patients.

We’re ready for an active week ahead engaging with the #biotech community! Logistics below. We look forward to sharing our progress and connecting with partners.

For #RareDiseaseDay, we came together to name our newest plush teammate, “Tira,” inspired by a zebra in Kenya born with a rare genetic condition that altered her stripe pattern.🦓Tira is a reminder of why we do this work and who we do it for.

More #WomeninSTEM below!

We have a fierce appreciation for women in STEM! On International Day of Women and Girls in Science, we recognize all of the incredible women at SpliceBio who are transforming the future of genetic medicines and are paving the way for future generations. #WomeninSTEM

Listen to the full episode on The BioHub Podcast.⬇️ Spotify: lnkd.in/e-6YHEBk Apple: lnkd.in/eyt85Zpx

#Stargardt disease is a condition that leads to central vision loss & blindness. Caused by biallelic mutations in the ABCA4 gene, it remains a significant unmet need with no approved treatments. This #LowVisionAwarenessMonth, learn how SB-007 targets the underlying genetic cause.

Details: splice.bio/splicebio-init…

We are pleased to announce that the first patient has been dosed in the Part B dose expansion portion of our Phase 1/2 ASTRA clinical trial of SB-007, a dual adeno-associated viral vector gene therapy for the treatment of #Stargardt disease.

Read here: businesswire.com/news/home/2026…

We're thrilled to welcome Don Munoz to SpliceBio as our CFO. With deep financial expertise and broad experience within the life sciences industry, Don will be instrumental as we enter our next stages of development and position SpliceBio for long-term value creation.